[Cisatracurium pharmacodynamics in renal transplantation].
OBJECTIVE
Cisatracurium seems to be beneficial, especially for patients with organ dysfunction, due to organ-independent Hofmann elimination and a lower trend to histamine release. This study aimed at determining cisatracurium pharmacodynamic profile in renal transplantation.


METHODS
Participated in this study 30 patients who were distributed in two groups: 15 healthy patients submitted to maxillofacial surgery, and 15 patients with chronic renal failure submitted to renal transplantation. All patients were anesthetized with etomidate, sufentanil and 0.5% to 1% sevoflurane . Intravenous cisatracurium was administrated after anesthetic induction and additional 0.05 mg.kg-1 was injected whenever T1 recovered 25%. Neuromuscular function was continuously monitored by acceleromyography using TOF stimulation, through supramaximal ulnar nerve stimulation.


RESULTS
Onset time (4.1 and 4.9 min), clinical duration (68.9 and 75.4 min) and recovery time (20.2 and 28 min) were similar between normal and renal failure groups, respectively. Time spent until T4/T1 > 0.7 (34.3 and 51.4 min), and > 0.9 (49.7 and 68.6 min) since the last 25% recovery of T1 were statistically different between groups, with the higher values observed in the renal failure group. Accumulation ratio was 1.08.


CONCLUSIONS
Onset, clinical duration and recovery time were comparable between groups. Time to T4/T1 > 0.7 and > 0.9 was longer in the renal failure group as compared to the normal group and cisatracurium did not show cumulative effects in the renal failure group.
Cavalcanti
Ismar Lima
IL
Hospital Geral de Nova Iguaçu, RJ, Brazil. ismarc@uol.com.br
Tardelli
Maria Angela
MA
Rodrigues
Rita de Cássia
Rde C